Injectable HIV treatment works for people with poor HIV control in Africa
New long-acting HIV drugs show promising early results
Broadly neutralising antibody N6LS could be part of long-acting HIV treatment
Lenacapavir plus broadly neutralising antibodies could be twice-yearly HIV treatment
The long-acting HIV treatment era is just beginning
Once-weekly combination of islatravir and lenacapavir safe and effective in 48-week study
Injectable HIV treatment underway in England and largely effective, but a couple of breakthrough cases raise concern
Caution advised when prescribing long-acting injectable cabotegravir and rilpivirine to avoid drug resistance
Adolescents prefer long-acting injectables to daily oral HIV treatment, study finds
